Therapeutic & IP optimization of provisionally-patented anti-inflammatory wound healing-accelerant

This project is performing translational studies on a wound-healing accelerant that has been provisionally patented. Animal studies showed that open skin wounds treated with this accelerant healed up to six times faster, even in otherwise subnormally healing, pre-diabetic, obese animals. This is a critical step toward being able to therapeutically and commercially optimize this invention for future veterinary and clinical use. Improved wound care is an important need in Minnesota, particularly in diabetic populations.

Psyncretis, Inc.
Frank H. Burton, PhD